Using groundbreaking studies to drive effective, new cancer treatments is the core principle of research at Atlantic Health System Cancer Care. In addition to featuring many of the nation’s top doctors and researchers, we have partnerships with industry and cooperative groups that allow us to provide our communities with the latest cancer clinical trials. Some of the cancers we treat include leukemia, pancreatic cancer, kidney cancer, colorectal cancer, prostate cancer, skin cancer (including melanoma and Merkel Cell skin cancer), thyroid cancer, lymphoma, head and neck cancer, endometrial cancer, gynecologic cancer, vulvar cancer and cervical cancer.
Community Oncology Research Program
The Atlantic Health Cancer Consortium (AHCC) – made up of leading health care systems across New Jersey – is the first NJ-based National Cancer Institute Community Oncology Research Program (NCORP). Our goal is to expand clinical trial access to adults and children, particularly ethnic and racial minorities, who are often underrepresented in cancer research. Studies will focus on cancer control, prevention, screening, care delivery, treatment, medical imaging and quality of life.
As the lead affiliate for NCORP community site activities, Atlantic Health System provides the scientific guidance and central support personnel necessary to achieve the program’s objectives. Additional members of the AHCC, which covers about 70% of the state’s population, include CentraState Medical Center, Holy Name Medical Center, Hunterdon Healthcare System and St. Peter’s Healthcare System.
Breakthrough Oncology Accelerator
Atlantic Health System Cancer Care has partnered with Translational Genomics Research Institute (TGen) of Phoenix, Arizona to improve patient access to the most innovative and sophisticated cancer therapies. Through this clinical collaboration, known as the Breakthrough Oncology Accelerator, we have opened multiple early and late-phase clinical trials, available at only a few centers around the world, right here in New Jersey. The BOA also included the creation of Morristown Medical Center’s Breakthrough Treatment Center, the first of its kind dedicated to highly-promising cancer therapies.
Pioneers in Cancer Research
With many of our clinical trials, such as our treatments for glioblastoma and HPV-associated cancers, we are one of only a handful of sites in the country offering them. Other accomplishments include:
- The Atlantic Melanoma Center was the first in the world to enroll a patient in a Phase IIa trial of a virus-based immunotherapy.
- Overlook Medical Center enrolled the most patients in the region (NJ, NY, CT, PA and DE) into the international TAILORx breast cancer study.
- The Women’s Cancer Center was one of six centers in the nation to participate in an MD Andersen Cancer Center clinical trial for the early detection of ovarian cancer.
- Morristown Medical Center is the only study site in New Jersey offering tumor infiltrating lymphocyte therapy (TIL) for the treatment of Stage IV melanoma and metastatic lung cancer. Learn more >
Growing Forward | Carol G. Simon Cancer Center
As a national leader in oncology, Morristown Medical Center’s Carol G. Simon Cancer Center tirelessly confronts the challenges posed by cancer, but therapies have grown more complex and an aging population has increased demand. Our proposed expansion will ensure that we continue to
provide the highest level of patient-centric, multidisciplinary treatment using the latest research and innovations. It includes 20 state-of-the-art surgical suites that co-locate exam rooms and clinical services to enhance care coordination and convenience. A combination of open and private infusion bays will also be made available. The hospital has undertaken these projects in multiple phases of construction and even though some are complete or near completion, the fundraising continues.